News
12-14-2009, 12:12 AM
Ipsen today announced the preliminary results of a phase I trial in metastatic breast cancer with BN83495, Ipsen’s lead and first-in-class orally available irreversible steroid sulfatase (STS) inhibitor.
More... (http://www.news-medical.net/news/20091214/Ipsen-announces-preliminary-results-of-phase-I-trial-in-metastatic-breast-cancer-with-BN83495.aspx)
More... (http://www.news-medical.net/news/20091214/Ipsen-announces-preliminary-results-of-phase-I-trial-in-metastatic-breast-cancer-with-BN83495.aspx)